Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2647 • 2016 ACR/ARHP Annual Meeting
Drug Trough Serum Levels Rather Than Antidrug Antibodies Explain Disease Flares in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with TNF Inhibitors in Clinical Remission/Low Disease Activity: A One Year Prospective, Multicenter Study (INMUNOREMAR)
Raimon Sanmarti¹, Jose Inciarte-Mundo¹, Paula Estrada², Maria García Manrique³, Javier Narváez⁴, Antonio Gomez-Centeno³, Jesús Rodríguez-Moreno⁴, Mariona Pascal⁵ and Jordi Yagüe⁵, ¹Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Moisès Broggi-Hospital General de L'Hospitalet - Consorci Sanitari Integral, Sant Joan Despí, Spain, ³Rheumatology Department, Hospital Parc Taulí, Sabadell, Spain, ⁴Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ⁵Immunology Department, Hospital Clinic de Barcelona, Barcelona, Spain
Background/Purpose: To determine predictive factors of disease flares, including drug trough serum levels and anti-drug antibodies (Ab) in patients with rheumatoid arthritis (RA) or polyarticular…
Abstract Number: 158 • 2016 ACR/ARHP Annual Meeting
Musculoskeletal Ultrasound Is a Sensitive Imaging Tool for the Assessment of Dynamic Changes of Bone Erosions in Inflammatory Arthritis: A Comparative Analysis with High-Resolution Peripheral Quantitatve Computed Tomography
Stephanie Finzel^1,2, Marina Backhaus³, Sebastian Kraus⁴, Georg Schett⁵ and Reinhard Voll⁶, ¹Department of Rheumatology and Clinical Immunology, Medical Faculty, University Medical Center, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine III, Rheumatology and Immunology, University of Erlangen, 91054, Germany, ³Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁴Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Dpt. Rheumatology & Clinical Immunology and Centre for Chronic Immunodeficiency, University Hospital Freiburg, University Medical Center, University of Freiburg, Freiburg, Germany
Background/Purpose: Correct detection of bone erosions is crucial both for diagnosis and for monitoring of treatment response in patients with inflammatory joint diseases. Musculoskeletal ultrasound…
Abstract Number: 1694 • 2016 ACR/ARHP Annual Meeting
Does Treat to Target or Achieving Remission Improve Radiographic Outcome in Psa?
Laura C. Coates^1,2, Elizabeth M.A. Hensor^1,3, Paul Emery⁴, Philip G. Conaghan¹ and Philip S. Helliwell⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Tight Control of PsA (TICOPA) study was the first to address treat to target in PsA using the minimal disease activity (MDA)…
Abstract Number: 2747 • 2016 ACR/ARHP Annual Meeting
Dapsa-28 May be Used Instead of Dapsa-66/68 in Psoriatic Arthritis
Umut Kalyoncu, Ozun Bayndır, Mustafa Ferhat Oksuz, Gezmis Kimyon, Abdulsamet Erden, Sule Yavuz, Gozde Cetin, Orhan Kucuksahin, Levent Kilic, Ahmet Omma, Cem Ozisler, Dilek Solmaz, Ahmet Mesut Onat, Bunyamin Kisacik, Duygu Ersozlu Bakirli, Muhammet Cinar, Abdurrahman Tufan, Fatih Yildiz, Ridvan Mercan, Timucin Kasifoglu, Baris Yilmazer, Sema Yilmaz, Kenan Aksu, Sukran Erten, Mehmet Sayarlioglu, Ediz Dalkilic, Servet Akar, Cengizhan Acikel, Muge Aydin Tufan, Ayse Balkarli, Esen Kasapoglu-Gunal, Soner Senel, Senol Kobak, M Tuncay Duruoz, Atalay Dogru, E.Figen Tarhan, Meryem Can, Lutfi Akyol, Seval Pehlevan, Funda Erbasan, Fatos Arslan, Adem Kucuk, Emel Gonullu, Yasemin Kabasakal, Mehmet Sahin, Nilgun Atakan and Sibel Z. Aydin, PsART study group, Ankara, Turkey
Background/Purpose: Disease Activity index for Psoriatic Arthritis (DAPSA) originally developed from patients with reactive arthritis and validated in psoriatic arthritis (PsA) patients. DAPSA includes…
Abstract Number: 543 • 2016 ACR/ARHP Annual Meeting
Synovial Features of Rheumatoid Arthritis and Psoriatic Arthritis Differ in Patients in Clinical and Ultrasound Remission after Anti-TNF Therapy
Stefano Alivernini¹, Luca Petricca¹, Laura Bui², Barbara Tolusso¹, Gabriele Di Sante¹, Roberta Benvenuto², Anna Laura Fedele¹, Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology - Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Histopathology - Institute of Pathology, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Persistent disease remission is the major goal of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) treatment. The combined use of clinical and ultrasound selection…
Abstract Number: 1703 • 2016 ACR/ARHP Annual Meeting
Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
Peter Nash¹, Kamal Ohson², Jessica Walsh³, Nikolay Delev⁴, Dianne Nguyen⁴, Lichen Teng⁴, Juan J Gomez-Reino⁵ and Jacob A Aelion⁶, ¹University of Queensland, Brisbane, Australia, ²Memorial University of Newfoundland, St. John's, NF, Canada, ³University of Utah School of Medicine, Salt Lake City, UT, ⁴Celgene Corporation, Summit, NJ, ⁵Hospital Clinico Universitario, Santiago, Spain, ⁶West Tennessee Research Institute, Jackson, TN
Background/Purpose: ACTIVE is the first apremilast (APR) trial that evaluated time to onset of efficacy beginning at Wk 2 in psoriatic arthritis (PsA) patients (pts)…
Abstract Number: 2930 • 2016 ACR/ARHP Annual Meeting
Specific Metabolic and Functional Changes in Peripheral CD8+ T Cells Specifically Distinguish RA from PSA and SPA
Rui Carvalho¹, Christine Tucher², Lars Tykocinski², Susanne Neu², Karel Klika³, H.-M. Lorenz² and Margarida Souto-Carneiro², ¹Life Sciences Department, FCTUC, Center for Functional Ecology, University of Coimbra, Coimbra, Portugal, ²Rheumatology, Department of Rheumatology, University of Heidelberg, Heidelberg, Germany, ³German Cancer Research Center, Heidelberg, Germany
Background/Purpose: Studies by our team and others have shown that CD8 T cells (CD8s) in RA have a pro-inflammatory, cytotoxic effector phenotype and may, therefore,…
Abstract Number: 103 • 2015 ACR/ARHP Annual Meeting
Axial Disease in Psoriatic Arthritis: Genetic Biomarkers of Psoriatic Spondyloarthritis
Deepak R. Jadon¹, John Bowes², Anne Barton³, Raj Sengupta¹, Alison L Nightingale⁴, Mark Lindsay⁵, Eleanor Korendowych¹, Graham Robinson⁶ and Neil J. McHugh⁷, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Centre for Musculoskeletal Research, Manchester, United Kingdom, ³Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom, ⁴Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Pharmacy & Pharmacology, University of Bath, Bath, United Kingdom, ⁶Royal United Hospital, Bath, United Kingdom, ⁷Rheumatology, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, United Kingdom
Background/Purpose: A lack of well-characterised clinical cohorts has impeded research of the genetics of axial disease in psoriatic arthritis (PsA). We sought to determine genetic…
Abstract Number: 2495 • 2015 ACR/ARHP Annual Meeting
Tele-Monitoring of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis
Alexander Langer¹ and Hans-Eckhard Langer², ¹Department of Computer Science, RWTH Aachen University, Aachen, Germany, ²RHIO (Rheumatology, Immunology, and Osteology), Duesseldorf, Germany
Background/Purpose: There is evidence that tight control of rheumatoid arthritis improves outcome. In daily practice this aim is constricted by logistic limitations such as a…
Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting
Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Julio Ramírez¹, Jose Inciarte-Mundo², Andrea Cuervo¹, Virginia Ruiz-Esquide², M. Victoria Hernández³, Raimon Sanmarti² and Juan D. Cañete², ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ³Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had higher disease…
Abstract Number: 2839 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Christopher J. Edwards¹, Francisco J. Blanco², Jeffrey Crowley³, ChiaChi Hu⁴, Kamal Shah⁴ and Charles A. Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Warren, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of…
Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Eirik Ikdahl¹, Jonny Hisdal², Silvia Rollefstad¹, Inge C Olsen³, Tore K. Kvien⁴, Terje R. Pedersen⁵ and Anne Grete Semb⁶, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway, ⁶Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…
Abstract Number: 2843 • 2015 ACR/ARHP Annual Meeting
Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Arthur Kavanaugh¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephen Hall⁵, Eric Lespessailles⁶, Philip J. Mease⁷, Georg A. Schett⁸, Kamal Shah⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²University of Sheffield, Sheffield, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Monash University, Melbourne, Australia, ⁶University of Orléans, Orléans, France, ⁷Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁸University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, has demonstrated clear efficacy and good tolerability in psoriatic arthritis (PsA) and psoriasis. Longer term data are…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 2849 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Arthur Kavanaugh¹, Dafna Gladman², Christopher J. Edwards³, Airi Poder⁴, Frederic Liote⁵, Paul A. Bird⁶, Georg Schett⁷, Melissa McIlraith⁸, Lichen Teng⁸ and Philip J. Mease⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³University Hospital Southampton, Southampton, United Kingdom, ⁴Clinical Research Centre Ltd, Tartu, Estonia, ⁵University Paris Diderot, Paris, France, ⁶University of New South Wales, Sydney, Australia, ⁷Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with active psoriatic arthritis (PsA) have disease involvement across multiple domains. Pts can have substantial fatigue, which is increasingly being recognized as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].